Wall Street and Silicon Valley have recently been making big new bets on potential breakthrough ways to treat obesity through novel therapeutics.

Los Altos, California based biotech company Alto Neuroscience has officially filed with the SEC to raise $100M USD in an IPO on the New York Stock Exchange.

BriaCell Therapeutics (NASDAQ: BCTX) has announced new positive data from their Phase II clinical trial for patients with advanced breast cancer.

1nhaler has developed a sustainable single use medical inhaler capable of delivering multiple types of dry powder drugs to patients.

Scientists at Northwestern University have developed a new technology that could be a breakthrough in simulating how new drugs will affect the human body.

Founder of iconic apparel company Lululemon (NASDAQ: LULU) is putting $100M into his venture fund to find a cure for facioscapulohumeral muscular dystrophy

Berkley, California based biomaterials startup Bolt Threads has entered into a deal to go public via a SPAC with Golden Arrow Merger Corp (NASDAQ: GAMC)

There’s a new biotech startup focused on cancer research. And the way they got funded might just be the future of scientific ventures.

Radiopharmaceutical treatments for cancer is a highly exciting area of biotech that has been attracting venture capital and public markets investment.

Wall Street hedge fund manager Steve Cohen has taken another big stake in a small publicly traded biotech company called Bionomics.